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defined to fit the model to the experimental data in terms of 
growth curve, dose response curves, TCD50 and α/β value. 
 
Results: The experimental data are well described for an O2-
independent response. For this case an α/β of 74.7 ± 5.5 Gy 
was obtained. 
When including the effects of O2, we aimed to reproduce this 
high experimental value starting from smaller intrinsic α/β 
values. Unexpected shifts towards lower doses of the 2-Fx 
curves with respect to the 1-Fx curves were observed. This 
effect could be explained by a strong reoxygenation between 
the 1st and the 2nd Fx. Known reoxygenation mechanisms in 
the model include shrinkage, angiogenesis and the increase 
of available O2 due to the presence of dead cells. The latter 
was found to be the dominant mechanism of the three. When 
switching off these mechanisms, the unexpected shifts were 
still observed. A fourth reoxygenation mechanism, which is 
inherent to the original model, was identified. It implicitly 
arises by assuming that the distributions of cells at specific 
O2 levels remained the same after irradiation. To eliminate 
this effect, the histograms were updated to consider the 
actual O2 levels of the surviving cells. After doing so, the 
unexpected shifts of the curves were no longer observed and 
higher simulated values of α/β were obtained. 
 
Conclusion: This work constitutes the first stage of 
experimental validation with preclinical data of a computer 
model which simulates the radiation response of hypoxic 
tumors. It was confirmed that reoxygenation plays an 
important role in the dose response of tumors. Additionally, 
important information on how to further improve the model 
was gathered.  
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Purpose or Objective: SABR (Stereotactic Ablative 
Radiotherapy) is only possible in a subset of patients with 
small tumors and favourable anatomy as the very high BED 
increases the risk of complications. Lung SABR is often 
delivered to tumors that are more peripheral thus; the ribs 
are structures now exposed to significantly higher doses than 
historically has been the case. The first fifty-two SABR 
(Stereotactic Ablative Radiotherapy) patients treated at our 
centre were monitored for rib fracture and chest pain. In this 
study, we fit the data to the LKB model of normal tissue 
response. 
 
Material and Methods: Fifty-two patients were treated with 
either, 55 Gy in 5# (40 patients), 60 Gy in 8# (6 patients) or 
54 Gy in 3# (6 patients) depending on the size and location of 
the tumor. For each patient a chest wall volume was 
delineated. The chest wall volume encompassed the rib and 
chest wall between the ribs. Data were fitted to the Lyman-
Kutcher-Burman (LKB) model, a model using the normal 
cumulative density function to produce a sigmoidal dose 
response curve. The model consists of three parameters 
TD50, which determines the dose at which 50% of treatments 
will result in a complication, m which governs and slope and 
the volume parameter, n. We assumed α/β = 3 Gy. 
 
Results: Of the 52 patients there were 5 occurrences of rib 
fracture (NTCP = 9.6% -6.4%/+11.4%). Leaving the volume 
parameter free in the fit produced best-fit parameters of n = 
0.01, TD50 = 370 Gy and m = 0.45. Due to the small NTCP it is 
difficult to extrapolate to find TD50. This is shown 
graphically in Figure 1; a small change in the slope will have 
a very large effect on the point at which the NTCP is equal to 
50%. Consequently, the uncertainties were large, n could not 
be constrained although very small values were preferred. At 
95% confidence TD50 > 220 Gy and m>0.2, assuming that rib 
fracture is approximately a serial complication. Figure 1 
shows the correlation between TD50 and m at the best-fit 
value of the volume parameter. 
 
 
Conclusion: We conclude that the rate of rib fracture is 
relatively low (<10%) in SABR patients. NTCP modelling 
suggests that a very low volume parameter is most consistent 
with the data. This is in agreement with what might be 
naively expected. Due to small number of patients and 
events analysed to date it is not possible to constrain 
parameters tightly. This may be helped be re-parameterising 
the curve. We are now studying the effects of low absolute 
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Purpose or Objective: Standard power calculation methods 
for randomized trials do not account for patient-to-patient 
differences in effect of novel radiotherapy (RT) techniques. 
The expected advantage of a new technique can often be 
related to heterogeneous dose metrics in individual patients. 
Here, we investigate if model-based outcome assessment can 
affect sample size requirements for a randomized trial of 
proton versus photon RT for lung cancer with reduction of 
severe radiation-induced lung toxicity (RILT) as primary 
endpoint. 
 
Material and Methods: We estimated the number of patients 
needed to demonstrate an advantage of proton versus photon 
RT in a randomized trial, with α=0.05 and 80% power. We 
simulated outcomes using Weibull survival distributions with 
baseline probability of freedom from RITL at 2 years of 85% 
for patients without clinical risk factors. Heterogeneous gain 
from proton therapy was quantified by change in mean lung 
dose (∆MLD), randomly normally distributed in the proton 
arm with mean 4.2 Gy and s.d. 2 Gy. ∆MLD values were 
translated into hazard ratios (HR) using the QUANTEC dose-
response relationship, adjusted for clinical prognostic factors 
(comorbidity, tumour location, smoking status, age) evenly 
distributed between the trial arms. Simulated follow-up was 
distributed over a time period of 2 years. Monte Carlo 
simulations (3000 per data point) were used to assess trial 
power. Sample size estimates were calculated as follows: 
Standard: Comparison of treatment arms using log-rank 
statistics; and Model-based: Cox proportional hazards 
regression fitted to the change in dosimetric predictor, here 
∆MLD. The consequence of a misspecified dose metric was 
assessed by assuming an underlying true effect metric that 
was correlated to, but not equal to, ∆MLD. 
 
Results: Sample size estimates differed considerably for the 
two approaches; see Table 1. 744 patients were needed to 
show the advantage of proton versus photon RT with standard 
comparison of trial arms, while superiority of protons based 
on a direct fit to the effect metric (∆MLD) required only 549 
patients. The advantage of using the model-based method 
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was maintained as long as the effect metric used for Cox 
regression had a linear correlation with the true effect 
metric of at least 0.50. The conclusions held if the trial 
cohort consisted of an expected high benefit population (22% 
reduced sample size), but the effect was even stronger if the 
cohort was a population with modest expected benefit (31% 




Conclusion: We have demonstrated that the required patient 
sample size for randomized trials in radiation oncology may 
be considerably reduced by taking heterogeneous dose-effect 
into account. Dual planning provides support for the 
statistical outcome modelling that increases trial power even 
if the dose-response model is moderately misspecified. The 
outcome of a trial in the example studied would be a 
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Purpose or Objective: Gastrointestinal (GI) toxicity is a side-
effect induced by whole pelvis intensity modulated 
radiotherapy (WP-IMRT), affecting importantly patients’ 
quality of life. The aim of this study was to identify 
predictors of diarrhea in a cohort of chemo-naÏf patients 
treated with WP-IMRT after prostatectomy. 
 
Material and Methods: The Inflammatory Bowel Disease 
questionnaire (IBDQ) was used to assess the degree of GI 
symptoms after WP-IMRT, investigating 4 distinct areas: 
bowel and systemic symptoms, emotional and social 
functions. This study focused on the most clinically relevant 
item 5 relative to the bowel domain, in order to evaluate the 
frequency of liquid defecation. Patient-reported scores at 
baseline, at RT mid-point and end, and every 3 months after 
RT end were prospectively collected . The responses are 
scored on a 7-point scale where 7 corresponds to the best 
function and 1 to the worst. Clinical/dosimetric data in 115 
patients treated with adjuvant (n=65) or salvage (n=50) WPRT 
in a single Institute were available (static field IMRT:19; 
VMAT:55; Tomotherapy:41). Dose–volume histograms (DVHs) 
for intestinal loops and sigmoid colon were calculated. The 
25th percentile of the score variation between baseline and 
half/end RT was considered as end-point (∆ -IBDQ5≤-3). 
Associations between diarrhea and clinical/DVH parameters 
were assessed by logistic uni- and backward multi-variable 
analyses. A previously introduced method based on DVH 
differences between patients with/without diarrhea toxicity 
was used to select the most discriminative DVH parameters. 
 
Results: No significant correlation emerged for sigmoid 
colon, then the analysis was focused on intestinal loops. 
Patients without basal score and with ∆ -IBDQ5≤-3 were 
excluded from the analysis: 23/77 pts showed acute GI 
toxicity. At univariate analysis, volumes receiving 5 to 40Gy 
(V5-V40) were correlated with ∆ -IBDQ5≤- 3 (p<0.03). 
Multivariate analysis confirmed a leading role of dosimetric 
variables, while no significant correlation for clinical 
parameters was found. Best cut-off values (assessed by ROC) 
discriminating patients with/without ∆ -IBDQ5≤-3 were: 
V20<250cc, V30<150cc and V40<90cc. The overall incidence 
equal to 10% and 50% resulted for the group of patients with 
DVH parameters lower/higher than thresholds, respectively 




Conclusion: Low-medium IMRT doses to intestinal loops were 
correlated to diarrhea symptom at half/end of RT. This study 
proposed new dose volume constraints, that may be used to 
prevent much radiation-induced GI morbidity. 
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Purpose or Objective: MRI-based focal tumour boosting is 
currently under clinical investigation for prostate cancer 
patients, e.g. in the FLAME trial. These highly conformal, 
focal dose distributions can be difficult to achieve with 
photons, depending on the size and location of the boost 
volume (i.e. proximity to critical organs at risk). Selected 
patients might therefore be candidates for proton therapy. In 
previous work we have established an MRI-based tumour 
control probability (TCP) model. Combined with published 
rectum and bladder normal tissue complication probability 
(NTCP) models we have in this study explored the use of 
biological (TCP and NTCP) models to identify prostate cancer 
patients that might be suitable candidates for proton therapy 
if treated according to FLAME-like trial protocols. 
 
Material and Methods: CT scans of seven patients from a 
prospective trial in our institution were used for planning. To 
obtain realistic boost geometries, MRI-based index tumours 
from a different cohort were used (matched on prostate 
volume), propagated with rigid registration on the prostate 
volume. VMAT plans (Eclipse, Varian Medical Systems) with 
and without a boost to the index lesion (95 Gy / 35 fx) were 
created; both plans delivered a conventional dose (77 Gy / 35 
